KPV is the Lys-Pro-Val tripeptide clipped from α-MSH’s C-terminus (residues 11 to 13), a compact ~342 Da fragment with the formula C16H30N4O4. Researchers are working with a molecule that strips away the His-Phe-Arg-Trp message core, so it shows no reported MC1R to MC5R activity. Its central proline adds backbone rigidity. Researchers study its proposed anti-inflammatory action via PepT1 uptake and NF-κB blockade in gut and skin models. There’s more worth knowing below.
Key Takeaways
- KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-MSH, corresponding to residues 11 to 13, with molecular formula C16H30N4O4 (~342.43 g/mol).
- Its central proline creates a rigid backbone kink, reducing flexibility across the two peptide bonds linking lysine, proline, and valine.
- KPV lies outside the His-Phe-Arg-Trp message core (residues 6 to 9), so it has no reported MC1R to MC5R receptor activity.
- Research focuses on receptor-independent anti-inflammatory effects in gut and skin models, proposing PepT1 uptake and NF-κB blockade.
- Unlike full-agonist α-MSH, KPV avoids pigmentation effects, making it a compact fragment about one-fifth the ~1665 Da parent hormone.
What is KPV peptide and where does it come from
KPV is a tripeptide made of three amino acids, lysine, proline, and valine, linked in a linear Lys-Pro-Val sequence. It carries the molecular formula C16H30N4O4 and a molecular weight near 342.43 g/mol. KPV corresponds to residues 11 to 13 at the C-terminus of α-MSH, a 13-amino-acid neuropeptide derived from POMC processing. So KPV isn’t an independent endogenous hormone, it’s the terminal three-amino-acid fragment of that larger parent peptide.
Notably, KPV lies outside α-MSH’s melanocortin receptor “message” core at residues 6 to 9 (His-Phe-Arg-Trp). Research catalogs typically supply it as a free acid or acetate salt. Across research profiles, sources consistently identify KPV as an α-MSH-derived fragment, preserving only the C-terminal tail rather than the receptor-activating message region.
How is KPV derived from alpha-MSH
KPV is the C-terminal fragment of α-MSH, specifically residues 11 to 13. α-MSH is a 13-residue neuropeptide that derives from POMC processing, and KPV represents only the terminal Lys-Pro-Val tail of that larger sequence.
When researchers isolate these three residues, researchers are taking only the C-terminal end, leaving behind the melanocortin “message” core at residues 6 to 9, His-Phe-Arg-Trp. That’s why KPV sits outside the receptor-activating motif. Researchers are working with a linear tripeptide linked by two peptide bonds, carrying a central proline that stiffens the backbone.
Researchers describe KPV as an α-MSH-derived fragment rather than an independent endogenous hormone. Researchers observe it referenced as the last three amino acids of the parent peptide, preserving structure without retaining the pigmentation-related signaling capacity of full-length α-MSH.
Why does the KPV tripeptide structure matter
The KPV tripeptide structure matters because the specific arrangement of Lys-Pro-Val determines everything about how KPV behaves. That central proline introduces a rigid backbone kink, constraining the tripeptide’s conformation and reducing the flexibility researchers would expect from such a short chain. With just two peptide bonds linking lysine, proline, and valine, researchers are working with a compact molecule of roughly 342 Da, about a fifth the mass of the 1665 Da parent hormone. This small size is why researchers cite KPV’s potential for cell entry and tissue transport in preclinical work. Researchers also notice the fragment sits outside α-MSH’s His-Phe-Arg-Trp message core, so it lacks the sequence needed to activate melanocortin receptors. The structure, then, explains both KPV’s transport behavior and its receptor-independent profile.
Which research applications study KPV
KPV research concentrates around inflammation, gut tissue, and skin models. In preclinical work, researchers examine KPV’s proposed anti-inflammatory action, often through PepT1-mediated uptake followed by intracellular suppression of inflammatory signaling. Researchers also observe attention on NF-κB blockade, which limits nuclear inflammatory transcription, plus interactions involving importin-related nuclear transport pathways. Gut-focused studies exploit PepT1 expression in intestinal tissue, and skin research explores the fragment’s receptor-independent profile that avoids α-MSH’s pigmentation effects. These applications remain confined to laboratory and animal studies. KPV isn’t FDA-approved, and human outcome data stays limited. The consensus researchers encounter frames KPV as a small C-terminal fragment with preclinical anti-inflammatory interest, not validated therapy.
How does KPV compare to full-length alpha-MSH
KPV differs from full-length alpha-MSH primarily in size and mechanism. Researchers are comparing a compact tripeptide against a 13-residue neuropeptide, and the differences drive their divergent research profiles.
| Property | Comparison |
|---|---|
| Size | KPV: 3 residues; α-MSH: 13 residues |
| Molecular weight | KPV: ~342 Da; α-MSH: ~1665 Da |
| Receptor core | KPV lacks His-Phe-Arg-Trp (residues 6 to 9) |
| MC1R to MC5R activity | KPV: none reported; α-MSH: full agonist |
| Anti-inflammatory action | KPV: receptor-independent; α-MSH: receptor-mediated |
Because KPV represents only residues 11 to 13, it omits the melanocortin “message” core, so researchers won’t see the pigmentation effects tied to α-MSH’s receptor activation. That distinction lets researchers explore KPV’s anti-inflammatory mechanisms, PepT1 uptake and NF-κB blockade, without confounding melanocortin signaling.
How to source and store research-grade KPV
Research-grade KPV requires confirming the supplier’s specifications match what the protocol requires. Check that the listed molecular formula reads C16H30N4O4 with a molecular weight near 342.43 g/mol, and verify whether researchers are receiving the free acid or acetate salt, since counterion content affects mass-based dosing. Request a certificate of analysis documenting purity by HPLC and identity by mass spectrometry.
For storage, keep lyophilized KPV sealed and desiccated at -20°C, where the linear tripeptide stays stable long-term. Reconstituted KPV should be aliquoted to avoid repeated freeze-thaw cycles that degrade peptide integrity. The proline-induced backbone rigidity helps structural stability, but researchers shouldn’t rely on that alone. Track lot numbers and expiration dates so the results stay reproducible across experiments.
Order Research-Grade KPV Peptides Today
When the research covers alpha-MSH fragments, gut barrier models, or inflammation studies, verified peptide quality is essential. Every batch of KPV and KLOW blend at Holas is backed by independent lab results for verified purity and batch consistency. Browse our full catalog or reach out to discuss the sourcing needs.
Frequently Asked Questions
Is KPV FDA-Approved for Any Human Medical Use?
No, KPV isn’t FDA-approved for any human medical use. Researchers find it described strictly as a research compound, not a marketed drug. The available evidence comes from preclinical laboratory and animal studies, primarily exploring anti-inflammatory activity in contexts like gut and skin tissue. Researchers shouldn’t treat it as an established therapeutic, since human clinical outcome data remains limited and hasn’t validated the benefits suggested in preclinical work.
What Is the Difference Between KPV Free Acid and Acetate Salt?
Researchers find the difference lies in the counterion and how the peptide’s supplied. The free acid is KPV in its base form, with the reported formula C16H30N4O4 and a molecular weight around 342.43 g/mol. The acetate salt pairs KPV with acetate, a common stabilizing counterion used in research catalogs. Both deliver the same Lys-Pro-Val tripeptide; researchers are just choosing between two standard supply forms for handling and solubility.
Are There Known Safety Concerns or Side Effects With KPV?
Researchers won’t find established human safety data for KPV, since the evidence base is entirely preclinical. It’s not FDA-approved and isn’t a marketed drug, so documented side effects and clinical outcome data don’t exist. Available summaries emphasize laboratory and animal studies rather than human validation. Researchers should treat any safety claims cautiously, because there’s no clinical trial evidence characterizing adverse effects, dosing limits, or long-term risks in clinical settings.
How Does KPV Differ From BPC-157 or Other Research Peptides?
Researchers find KPV’s a tripeptide (Lys-Pro-Val), a C-terminal α-MSH fragment weighing about 342 Da, studied mainly for receptor-independent anti-inflammatory activity via PepT1 uptake and NF-κB blockade. That’s distinct from BPC-157, a 15-amino-acid synthetic fragment derived from a gastric protein, researched more for tissue repair and angiogenesis. They differ in origin, size, and mechanism. Both remain preclinical, neither’s FDA-approved or validated by human clinical outcome data.
What Dosages Are Used in Preclinical KPV Studies?
Preclinical KPV studies report activity at very low concentrations rather than a single standardized dose. In cell-culture work, KPV is typically effective in the nanomolar range, with anti-inflammatory readouts such as NF-κB suppression and cytokine reduction observed at nanomolar to low-micromolar concentrations. In rodent colitis models, KPV has been studied through oral and systemic delivery, and targeted formulations such as self-immolative proKPV conjugates achieve comparable effects at roughly a 20-fold lower amount than free KPV by concentrating it at inflamed colonic tissue. Exact figures vary by model, delivery method, and endpoint, so specific values are best drawn from the primary preclinical literature for each study.
